

Korean startup Lunit commercialises AI solution suite for radiology in Canada

23 June 2022 | News

Following last year's USFDA clearance, Lunit's Canadian commercial approval to accelerate expansion in the North American market

South Korea-based startup Lunit has received commercial approval in Canada for Lunit INSIGHT, the company's AI solution suite for radiology. Canadian medical device regulator Health Canada issued class 2 medical licenses for Lunit's AI solution for chest x-ray, 'Lunit INSIGHT CXR' and 'Lunit INSIGHT MMG,' AI solution for mammography.

Lunit INSIGHT CXR detects suspicious lesions in chest x-ray images, helping radiologists distinguish suspected disease areas by providing the location of the lesion with an abnormality score that reflects the AI's confidence level. Trained with over 3,500,000 clinically proven data sets, Lunit INSIGHT CXR can detect 10 of the most common chest abnormalities, including supporting tuberculosis screening, with 97-99% accuracy.

Along with Lunit's AI solution for chest x-rays, Lunit INSIGHT MMG is one of the company's most mature radiology products, analyzing mammography images with high speed and 96% accuracy. The product is trained with more than 240,000 data sets, including over 50,000 biopsy-proven breast cancer cases, and has shown to reduce the chances of undetected breast cancer cases by 50% in mammogram screenings.

As the eighth largest in the world, the Canadian medical device market is growing rapidly along with the country's aging population. According to Statistics Canada, the number of persons aged 65 or older is expected to increase from approximately 17% of the total population in 2019 to approximately 23% in 2031.